Norway-based Ultimovacs ASA announced today that its universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab, demonstrated a 60% objective response rate (ORR) in metastatic malignant melanoma. All patients in this ...
from Google Alert - health https://ift.tt/3oE1wsz
via IFTTT
0 comments:
Post a Comment